Trial Profile
A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2022
Price :
$35
*
At a glance
- Drugs Dacarbazine (Primary) ; Ramucirumab (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms RamuNet
- 12 Nov 2021 Trial design published in the BMC Cancer.
- 01 Jun 2020 Status changed from not yet recruiting to recruiting.
- 28 Sep 2018 New trial record